Cargando…

Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies

CONTEXT: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is typically treated with lifelong supraphysiologic doses of glucocorticoids (GCs). Tildacerfont, a corticotropin-releasing factor type-1 receptor antagonist, may reduce excess androgen production, allowing for GC dose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarafoglou, Kyriakie, Barnes, Chris N, Huang, Michael, Imel, Erik A, Madu, Ivy-Joan, Merke, Deborah P, Moriarty, David, Nakhle, Samer, Newfield, Ron S, Vogiatzi, Maria G, Auchus, Richard J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Online Only Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530725/ https://www.ncbi.nlm.nih.gov/pubmed/34146101 http://dx.doi.org/10.1210/clinem/dgab438

Ejemplares similares

Tildacerfont for the Treatment of Patients With Classic Congenital Adrenal Hyperplasia: Results From a 12-Week Phase 2 Clinical Trial in Adults With Classic CAH
por: Auchus, Richard Joseph, et al.
Publicado: (2021)

Correction to: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies
Publicado: (2022)

Assessment of Steroid Hormones in Both Saliva and Blood During a Phase 2 Clinical Trial for the Use of Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia
por: Keevil, Brian, et al.
Publicado: (2021)

OR18-4 Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia
por: Auchus, Richard, et al.
Publicado: (2022)

Crinecerfont, a CRF(1) Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia
por: Newfield, Ron S, et al.
Publicado: (2023)

OR25-03 The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Results from A Multiple-Dose Phase 2 Study
por: Auchus, Richard J, et al.
Publicado: (2020)

Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia
por: Auchus, Richard J, et al.
Publicado: (2021)

Changes in Adrenal and Gonadal Androgens After 14-Day Treatment With CRF1 Receptor Antagonist, Crinecerfont (NBI-74788), in Men With Classic 21-Hydroxylase Deficiency
por: He, Xin, et al.
Publicado: (2021)

Cognitive Function of Children and Adolescents With Congenital Adrenal Hyperplasia: Importance of Early Diagnosis
por: Messina, Valeria, et al.
Publicado: (2020)

Characteristics of Growth in Children With Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency During Adrenarche and Beyond
por: Troger, Tobias, et al.
Publicado: (2021)

SAT286 Effect of Tildacerfont On Gonadotropins And Testicular Steroidogenesis In Men With Classic 21-hydroxylase Deficiency
por: Will Charlton, R, et al.
Publicado: (2023)

Case Report: Anastrozole as a monotherapy for pre-pubertal children with non-classic congenital adrenal hyperplasia
por: Liu, Sandy C., et al.
Publicado: (2023)

Block and Replace—a New Therapeutic Concept in Congenital Adrenal Hyperplasia?
por: Reisch, Nicole
Publicado: (2021)

Attention-Deficit/Hyperactivity Disorder Among US Children and Adolescents With Congenital Adrenal Hyperplasia
por: Harasymiw, Lauren A, et al.
Publicado: (2020)

A Multiclassifier System to Identify and Subtype Congenital Adrenal Hyperplasia Based on Circulating Steroid Hormones
por: Ye, Lei, et al.
Publicado: (2022)

Salivary Profiles of 11-oxygenated Androgens Follow a Diurnal Rhythm in Patients With Congenital Adrenal Hyperplasia
por: Nowotny, Hanna Franziska, et al.
Publicado: (2021)

Increased Prevalence of Fractures in Congenital Adrenal Hyperplasia: A Swedish Population-based National Cohort Study
por: Falhammar, Henrik, et al.
Publicado: (2021)

Production of 11-Oxygenated Androgens by Testicular Adrenal Rest Tumors
por: Schröder, Mariska A M, et al.
Publicado: (2021)

Nonvirilized Genitalia in 3 Female Newborns With the Salt-Wasting Congenital Adrenal Hyperplasia Phenotype
por: Yauch, Lauren, et al.
Publicado: (2020)

Individualizing Management of Infertility in Classic Congenital Adrenal Hyperplasia and Testicular Adrenal Rest Tumors
por: Jha, Smita, et al.
Publicado: (2019)

Health-related quality of life in children with congenital adrenal hyperplasia
por: Halper, Alyssa, et al.
Publicado: (2017)

Interpretation of Steroid Biomarkers in 21-Hydroxylase Deficiency and Their Use in Disease Management
por: Sarafoglou, Kyriakie, et al.
Publicado: (2023)

Positive fertility outcomes in a female with classic congenital adrenal hyperplasia following bilateral adrenalectomy
por: Dagalakis, Urania, et al.
Publicado: (2016)

Dose Escalating and Bioavailability Phase 1 Studies Assessing Safety and Tolerability and Pharmacokinetics of Tildacerfont, a Small-Molecule CRF1 Receptor Antagonist
por: Barnes, Chris, et al.
Publicado: (2021)

Depressive and anxiety disorders and antidepressant prescriptions among insured children and young adults with congenital adrenal hyperplasia in the United States
por: Harasymiw, Lauren A., et al.
Publicado: (2023)

Management of the Adult with Congenital Adrenal Hyperplasia
por: Auchus, Richard J.
Publicado: (2010)

Central Adrenal Insufficiency Is Rare in Adults With Prader–Willi Syndrome
por: Rosenberg, Anna G W, et al.
Publicado: (2020)

Musculoskeletal Features in Adults With X-linked Hypophosphatemia: An Analysis of Clinical Trial and Survey Data
por: Javaid, Muhammad Kassim, et al.
Publicado: (2021)

Management challenges and therapeutic advances in congenital adrenal hyperplasia
por: Mallappa, Ashwini, et al.
Publicado: (2022)

SAT-069 A Case of Congenital Hypoaldosteronism Due to Aldosterone Synthase Deficiency Misdiagnosed as Classic Congenital Adrenal Hyperplasia
por: Mallappa, Ashwini, et al.
Publicado: (2019)

Residual Adrenal Function in Autoimmune Addison’s Disease—Effect of Dual Therapy With Rituximab and Depot Tetracosactide
por: Napier, Catherine, et al.
Publicado: (2019)

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2022)

SUN-037 Discordant Serum 17-hydroxyprogesterone and Androstenedione in the Management of Congenital Adrenal Hyperplasia: Are 11-oxygenated Androgens Useful?
por: Jha, Smita, et al.
Publicado: (2020)

An integrated PK‐PD model for cortisol and the 17‐hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia
por: Al‐Kofahi, Mahmoud, et al.
Publicado: (2020)

Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia
por: Prete, Alessandro, et al.
Publicado: (2021)

MON-171 Characterization of the Adrenal Gland and Adrenal Rest Tissues in Congenital Adrenal Hyperplasia
por: Kolli, Vipula, et al.
Publicado: (2020)

Adrenal Tumor Mimicking Non-Classic Congenital Adrenal Hyperplasia
por: Tsai, Wen-Hsuan, et al.
Publicado: (2020)

The management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartum
por: Maher, Jacqueline Yano, et al.
Publicado: (2022)

Non-Classical Congenital Adrenal Hyperplasia in Childhood
por: Kurtoğlu, Selim, et al.
Publicado: (2017)

Cohort Profile: The National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) research dataset
por: Wang, Tingyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0tbhm4o1e5hoeff2bcktbfqbr9